Given that more than 40 times more LPA is observed in both the plasma and the ascites of ovarian cancer patients [10], and that DDR2 is associated with poor clinical outcomes in ovarian cancer patients [20,21], we explore the role of DDR2 in LPA-induced ovarian cancer cell invasion. Here, DDR2 is linked to ovarian cancer.